Lars A Christersson

Title: Innovations by Lars A. Christersson

Introduction

Lars A. Christersson is a notable inventor based in Amherst, NY (US). He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of periodontitis. With a total of 2 patents, his work has had a meaningful impact on dental health.

Latest Patents

Christersson's latest patents include a pharmaceutical composition for the treatment of periodontitis. This innovative combination of Metronidazole and Amoxicillin has been unexpectedly found to effectively treat periodontitis when administered in conventional therapeutic doses. Additionally, he has developed monoclonal antibodies useful in the identification of microorganisms, specifically targeting Actinobacillus actinomycetemcomitans, which is frequently implicated in juvenile periodontitis. These monoclonal antibodies are designed to be employed as reagents that include an inert carrier, such as buffered saline solution, to ensure proper dispersal of bacteria and preserve the integrity of antigens.

Career Highlights

Lars A. Christersson is affiliated with the State University of New York, where he continues to advance research in his field. His work has been instrumental in developing effective treatments for periodontal diseases, showcasing his dedication to improving dental health.

Collaborations

Throughout his career, Christersson has collaborated with esteemed colleagues such as Robert J. Genco and Joseph J. Zambon. These partnerships have further enhanced the quality and impact of his research.

Conclusion

Lars A. Christersson's contributions to the field of pharmaceuticals, particularly in the treatment of periodontitis, highlight his innovative spirit and commitment to advancing dental health. His patents and collaborations reflect a significant dedication to improving clinical outcomes in dentistry.